Maccura Biotechnology Co Ltd (300463)

Shenzhen

Currency in CNY

14.60

+0.26(+1.81%)

Closed02:44:59

Fair Value

Day's Range

14.30

14.61

52 wk Range

9.90

17.31

300463 Income Statement

Featured here, the Income Statement (earnings report) for Maccura Biotechnology Co Ltd, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Advanced Income Statement

Period Ending:

2014

31/12

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2022

01/01

2023

01/01

2023

31/12

Total Revenues

3,222.96

3,703.88

3,980.65

3,608.41

2,895.77

Total Revenues Growth

+20.02%

+14.92%

+7.47%

-9.35%

-19.75%

Cost Of Revenues

1,590.81

1,796.2

1,740.31

1,711.63

1,384.21

Gross Profit

1,632.14

1,907.68

2,240.34

1,896.79

1,511.56

Gross Profit Growth

+18.87%

+16.88%

+17.44%

-15.33%

-20.31%

Gross Profit Margin %

50.64%

51.5%

56.28%

52.57%

52.2%

Other Operating Expenses, Total

872.32

880.9

999.91

1,081.25

1,179.96

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+18.11%	+0.98%	+13.51%	+8.13%	+9.13%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	140.14	202.07	207.27	273.22	324.17
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	722.83	657.34	763.87	786.01	844.06
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	9.36	21.48	28.77	22.02	11.73

Operating Income

759.82

1,026.78

1,240.43

815.54

331.6

Operating Income Growth

+19.75%

+35.13%

+20.81%

-34.25%

-59.34%

EBIT Margin %

23.58%

27.72%

31.16%

22.6%

11.45%

Net Interest Expenses

-63.42

-63.85

-53.87

-10.9

-14.91

Net Interest Expenses Growth

-48.47%

-0.68%

+15.63%

+79.76%

-36.73%

Interest Expense, Total

-67.33

-68.19

-59.27

-35.06

-33.53

Interest And Investment Income

3.91

4.33

5.4

24.15

18.62

Other Non Operating Expenses, Total

-2.53

-8.23

-5.18

8.54

-1.27

EBT, Excl. Unusual Items

693.87

954.69

1,181.37

813.17

315.42

Gain (Loss) On Sale Of Assets

0.05

0.94

-4.05

-4.12

-4.17

Other Unusual Items, Total

-0.74

14.13

9.8

-10.86

1.19

EBT, Incl. Unusual Items

693.17

969.77

1,187.13

789.08

305.37

EBT, Incl. Unusual Items Growth

+16.17%

+39.9%

+22.41%

-33.53%

-61.3%

EBT, Incl. Unusual Items Margin

21.51%

26.18%

29.82%

21.87%

10.55%

Income Tax Expense

127.49

148.41

184.88

87.38

0.69

Net Income to Company

565.68

821.35

1,002.25

701.71

304.68

Minority Interest

-40.42

-27.44

-45.64

6.48

7.94

Net Income

525.26

793.92

956.6

708.18

312.62

Net Income Growth

+18.06%

+51.15%

+20.49%

-25.97%

-55.86%

Net Income Margin %

16.3%

21.43%

24.03%

19.63%

10.8%

Preferred Dividend and Other Adjustments

0.61

-

-

-

-

Net Income to Common Excl. Extra Items

524.65

793.92

956.6

708.18

312.62

Basic EPS - Continuing Operations

0.95

1.43

1.73

1.17

0.51

Basic EPS - Continuing Operations Growth

+18.1%

+50.94%

+20.77%

-32.25%

-56.2%

Diluted EPS - Continuing Operations

0.94

1.42

1.72

1.17

0.51

Diluted EPS - Continuing Operations Growth

+17.16%

+51.23%

+20.62%

-32.18%

-56.19%

Basic Weighted Average Shares Outstanding

552.59

553.99

552.69

603.94

608.68

Diluted Weighted Average Shares Outstanding

557.7

557.41

556.81

607.83

612.5

Dividend Per Share

0.19

0.43

0.47

0.35

0.15

Dividend Per Share Growth

+18.15%

+127.83%

+9.3%

-25.85%

-55.89%

EBITDA

915.32

1,232

1,462.97

1,068.09

625.35

EBITDA Growth

+21.02%

+34.6%

+18.75%

-26.99%

-41.45%

EBITDA Margin %

28.4%

33.26%

36.75%

29.6%

21.6%

EBIT